Status:
UNKNOWN
PP13 and Doppler Study to Predict Preeclampsia
Lead Sponsor:
Ben-Gurion University of the Negev
Collaborating Sponsors:
Diagnostic Technologies Ltd.
Perkin Elmer Inc.
Conditions:
Preeclampsia
Eligibility:
FEMALE
16-45 years
Phase:
PHASE2
PHASE3
Brief Summary
Assessment of biochemical and sonographic marker to predict the risk for developing preeclampsia Among biochemical markers are serum level of Placental Protein 13 (PP13) and Placenta Growth factor (PI...
Detailed Description
This is a prospective observational study enrolling all comers who attend the prenatal clinic for first trimester assessment of the risk for Down syndrome. All women are providing medical and obstetri...
Eligibility Criteria
Inclusion
- Women age 16-45 with viable pregnancy as defined by CRL and after signing on an informed consent
- In group 1 all patients meeting the above are eligible when GA is below 14 weeks
- In grop 2 all patients
Exclusion
- Gestation age at enrolment \> 13 weeks and 6 days by LMP verified by ultrasound at blood taking
- Mental retardation or other mental disorders that impose doubts regarding the patient's true willingness to participate in the Study
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00928213
Start Date
August 1 2009
End Date
December 1 2010
Last Update
June 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Soroka Medical Center, Ben Gurion University
Beersheba, Israel